Glooko Announces Integration of Wearable Activity & Biometric Monitors into Diabetes Management Platform

Share Article

Glooko builds on its leadership position in diabetes population management by allowing activity, blood pressure, and weight data, in conjunction with blood glucose data, to be used in clinical care.

"Access to biometric data like activity and blood pressure means our platform can be used to correlate blood glucose to lifestyle behavior to a degree not previously possible." - Rick Altinger, Glooko CEO

Glooko Inc., announced today the integration of activity, weight and blood pressure data from leading wearable activity and biometric monitors into its mobile, software as a service (SaaS) diabetes remote monitoring and population management platform. For the first time, data from fitness monitors including Fitbit®, iHealth®, Jawbone®, Moves, RunKeeper, Strava, and Withings® can be correlated and visualized against the verified blood glucose readings that Glooko currently liberates from more than 30 popular blood glucose meters using its MeterSync™ Blue technology.

With this latest innovation Glooko addresses the long-standing challenge faced by patients with diabetes of monitoring physical activity and food intake, in addition to their blood glucose levels, all of which are paramount to diabetes and chronic disease management. Physical activity has a significant impact on a patient’s blood glucose level so now patients and their care team will more clearly see the cause and effect relationship between the two. Traditional mHealth solutions requiring manual entry of this data have struggled to deliver the accuracy required for healthcare systems and payer groups to cost-effectively engage their diabetes populations. Glooko builds on its device-agnostic platform focused on data accessibility and advanced analytics for diabetes management.

"Physical activity is one of the major causes of hypoglycemia in individuals with diabetes. Daytime exercise will often have a delayed effect on the glucose levels and lead to nighttime hypoglycemia,” said Howard Wolpert, MD, Director of the Joslin Insitute of Technology Translation. “The integration of activity data from wearable devices into the Joslin HypoMap™ powered by Glooko™ will help individual patients identify their own individual specific activity threshold that is predictive of overnight lows. We will be able to provide patients with alerts when they reach their hypoglycemia risk threshold, so that they can take preemptive steps – such as adjusting their insulin doses or eating a snack – to prevent hypoglycemia. This is one of the first steps in our vision of building a diabetes care ecosystem that will provide remote, intelligent, 24-7 guidance to patients with diabetes everywhere."

“Access to biometric data like activity and blood pressure means our platform can be used to correlate blood glucose to lifestyle behavior to a degree not previously possible,” added Rick Altinger, Glooko CEO. “In the future, Glooko intends to use physician prescriptions to drive algorithms that utilize a patient’s level of activity along with retrospective glucose levels to make medication and insulin adjustment recommendations.”

About Glooko Inc.

Glooko is an innovative Silicon Valley company that delivers a FDA-cleared, HIPAA-compliant SaaS and mobile platform designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management platform includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes-centric analytics and supplies standardized reports, risk flags and insights to health systems and payers via API’s and web-based tools.

Glooko was founded in 2011 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vikram Singh
Glooko, Inc.
Email >
Follow us on
Visit website